Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ovarian Neoplasms

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 387 articles:
HTML format



Single Articles


    September 2022
  1. YFAT K, Mariam K, Mario B, Hal H, et al
    Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
    Gynecol Oncol. 2022 Sep 22. pii: S0090-8258(22)00574.
    PubMed     Abstract available


  2. WICKLINE M, Wolpin S, Cho S, Tomashek H, et al
    Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study.
    Gynecol Oncol. 2022 Sep 20. pii: S0090-8258(22)01825.
    PubMed     Abstract available


  3. HOU JY, Chapman JS, Kalashnikova E, Pierson W, et al
    Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 15. pii: S0090-8258(22)00590.
    PubMed     Abstract available


  4. YU S, Yang R, Xu T, Li X, et al
    Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
    Gynecol Oncol. 2022 Sep 13. pii: S0090-8258(22)00589.
    PubMed     Abstract available


  5. LI N, Zhu X, Nian W, Li Y, et al
    Blood-based DNA methylation profiling for the detection of ovarian cancer.
    Gynecol Oncol. 2022 Sep 9. pii: S0090-8258(22)00480.
    PubMed     Abstract available


  6. VAN STEIN RM, Engbersen MP, Stolk T, Lopez-Yurda M, et al
    Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer.
    Gynecol Oncol. 2022 Sep 7. pii: S0090-8258(22)00576.
    PubMed     Abstract available


  7. MENZIES AV, Usher EC, Hsu FC, Levine EA, et al
    HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
    Gynecol Oncol. 2022 Sep 6. pii: S0090-8258(22)00569.
    PubMed     Abstract available


  8. LAGO V, Segarra-Vidal B, Cappucio S, Angeles MA, et al
    OVA-LEAK: Prognostic score for colo-rectal anastomotic leakage in patients undergoing ovarian cancer surgery.
    Gynecol Oncol. 2022 Sep 1. pii: S0090-8258(22)00542.
    PubMed     Abstract available


  9. VAN DEN HEERIK ASVM, Aiyer KTS, Stelloo E, Jurgenliemk-Schulz IM, et al
    Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
    Gynecol Oncol. 2022;166:530-537.
    PubMed     Abstract available


    August 2022
  10. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    How does patient-centered communication in ovarian cancer care enhance patient well-being? A mixed methods study.
    Gynecol Oncol. 2022 Aug 31. pii: S0090-8258(22)00573.
    PubMed     Abstract available


  11. BOKKERS K, Frederix GWJ, Velthuizen ME, van der Aa M, et al
    Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    Gynecol Oncol. 2022 Aug 25. pii: S0090-8258(22)00550.
    PubMed     Abstract available


  12. THOMAS QD, Boussere A, Classe JM, Pomel C, et al
    Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
    Gynecol Oncol. 2022 Aug 12. pii: S0090-8258(22)00543.
    PubMed     Abstract available


  13. KUMAR A, Wang C, Sheedy SP, McCauley BM, et al
    Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Gynecol Oncol. 2022 Aug 2. pii: S0090-8258(22)00492.
    PubMed     Abstract available


  14. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Corrigendum to "Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer" [Gynecologic Oncology, Volume 165, Issue 2, May 2022, Pages 270-280].
    Gynecol Oncol. 2022;166:370-371.
    PubMed    


    July 2022
  15. HOARE JI, Hockings H, Saxena J, Silva VL, et al
    A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecol Oncol. 2022 Jul 30. pii: S0090-8258(22)00511.
    PubMed     Abstract available


  16. JOLY F, Fabbro M, Berton D, Lequesne J, et al
    Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00426.
    PubMed     Abstract available


  17. LIANG MI, Simons JL, Herbey I, Wall JA, et al
    Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 25. pii: S0090-8258(22)00493.
    PubMed     Abstract available


  18. KIM SI, Kim JH, Noh JJ, Kim SH, et al
    Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
    Gynecol Oncol. 2022 Jul 18. pii: S0090-8258(22)00483.
    PubMed     Abstract available


  19. CHASE DM, Marin MR, Backes F, Han S, et al
    Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
    Gynecol Oncol. 2022 Jul 15. pii: S0090-8258(22)00432.
    PubMed     Abstract available


  20. HARE CJ, Crangle C, McGarragle K, Ferguson SE, et al
    Change in cancer-related fatigue over time predict health-related quality of life in ovarian cancer patients.
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00433.
    PubMed     Abstract available


  21. PITIYARACHCHI O, Friedlander M, Java JJ, Chan JK, et al
    What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (>/=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemothera
    Gynecol Oncol. 2022 Jul 11. pii: S0090-8258(22)00436.
    PubMed     Abstract available


  22. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    PubMed     Abstract available


  23. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    PubMed     Abstract available


  24. TSENG JH, Bristow RE
    Complications associated with cytoreductive surgery for advanced ovarian cancer: Surgical timing and surmounting obstacles.
    Gynecol Oncol. 2022;166:5-7.
    PubMed    


  25. HANDLEY KF, Sood AK, Molin GZD, Westin SN, et al
    Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
    Gynecol Oncol. 2022;166:50-56.
    PubMed     Abstract available


  26. O'CEARBHAILL RE, Perez-Fidalgo JA, Monk BJ, Tusquets I, et al
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Gynecol Oncol. 2022;166:36-43.
    PubMed     Abstract available


    June 2022
  27. WALL JA, Lipking K, Smith HJ, Huh WK, et al
    Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
    Gynecol Oncol. 2022 Jun 28. pii: S0090-8258(22)00420.
    PubMed     Abstract available


  28. DICKEN BJ, Billmire DF, Rich B, Hazard FK, et al
    Utility of frozen section in pediatric and adolescent malignant ovarian nonseminomatous germ cell tumors: A report from the children's oncology group.
    Gynecol Oncol. 2022 Jun 21. pii: S0090-8258(22)00417.
    PubMed     Abstract available


  29. KEUNECKE C, Kulbe H, Dreher F, Taube ET, et al
    Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
    Gynecol Oncol. 2022 Jun 20. pii: S0090-8258(22)00414.
    PubMed     Abstract available


  30. KIM NR, Lee AJ, Yang EJ, So KA, et al
    Minimally invasive surgery versus open surgery in high-risk histologic endometrial cancer patients: A meta-analysis.
    Gynecol Oncol. 2022 Jun 17. pii: S0090-8258(22)00404.
    PubMed     Abstract available


  31. CAMPBELL R, Costa DSJ, Stockler MR, Lee YC, et al
    Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
    Gynecol Oncol. 2022 Jun 16. pii: S0090-8258(22)00335.
    PubMed     Abstract available


  32. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecol Oncol. 2022 Jun 8. pii: S0090-8258(22)00331.
    PubMed     Abstract available


  33. LOF P, van de Vrie R, Korse CM, van Gent MDJM, et al
    Can serum human epididymis protein 4 (HE4) support the decision to refer a patient with an ovarian mass to an oncology hospital?
    Gynecol Oncol. 2022 Jun 7. pii: S0090-8258(22)00336.
    PubMed     Abstract available


  34. NASIOUDIS D, Mastroyannis SA, Ko EM, Haggerty AF, et al
    Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
    Gynecol Oncol. 2022 Jun 3. pii: S0090-8258(22)00314.
    PubMed     Abstract available


  35. GERSHENSON DM, Sun CC, Westin SN, Eyada M, et al
    The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
    Gynecol Oncol. 2022;165:560-567.
    PubMed     Abstract available


  36. HOU X, Zhai Y, Hu K, Liu CJ, et al
    Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.
    Gynecol Oncol. 2022;165:552-559.
    PubMed     Abstract available


    May 2022
  37. BROEKMAN KE, van der Aa MA, Nijman HW, Jalving M, et al
    End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis.
    Gynecol Oncol. 2022 May 23. pii: S0090-8258(22)00258.
    PubMed     Abstract available


  38. TYMON-ROSARIO JR, Manara P, Manavella DD, Bellone S, et al
    Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Gynecol Oncol. 2022 May 19. pii: S0090-8258(22)00305.
    PubMed     Abstract available


  39. WANG CC, Al-Rubaye R, Tran V, Montemorano L, et al
    Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00307.
    PubMed     Abstract available


  40. HINCHCLIFF E, Westin SN, Herzog TJ
    State of the science: Contemporary front-line treatment of advanced ovarian cancer.
    Gynecol Oncol. 2022 May 16. pii: S0090-8258(22)00275.
    PubMed    


  41. ANGELES MA, Hernandez A, Perez-Benavente A, Cabarrou B, et al
    The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2022 May 11. pii: S0090-8258(22)00278.
    PubMed     Abstract available


  42. GUIDA F, Dioun S, Fagotti A, Melamed A, et al
    Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2022 May 9. pii: S0090-8258(22)00218.
    PubMed     Abstract available


    April 2022
  43. WILHITE AM, Baca Y, Xiu J, Paladugu R, et al
    Molecular profiles of endometrial cancer tumors among Black patients.
    Gynecol Oncol. 2022 Apr 27. pii: S0090-8258(22)00255.
    PubMed     Abstract available


  44. FU Z, Taylor S, Modugno F
    Lifetime ovulations and epithelial ovarian cancer risk and survival: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Apr 23. pii: S0090-8258(22)00214.
    PubMed     Abstract available


  45. WANG D, Jia S, Jia C, Cao D, et al
    Oncological and reproductive outcomes after fertility-sparing surgery in patients with seromucinous borderline ovarian tumor: Results of a large retrospective study.
    Gynecol Oncol. 2022 Apr 22. pii: S0090-8258(22)00215.
    PubMed     Abstract available


  46. LOF P, Retel VP, Algera MD, van Gent MDJM, et al
    Clinical implementation of routine diagnostic laparoscopy to guide initial treatment in patients with advanced-stage epithelial ovarian cancer in Dutch clinical practice: Evaluation of support and a budget impact analysis.
    Gynecol Oncol. 2022 Apr 9. pii: S0090-8258(22)00210.
    PubMed     Abstract available


  47. GERSEKOWSKI K, Delahunty R, Alsop K, Goode EL, et al
    Germline BRCA variants, lifestyle and ovarian cancer survival.
    Gynecol Oncol. 2022 Apr 7. pii: S0090-8258(22)00202.
    PubMed     Abstract available


  48. NORPPA N, Staff S, Helminen M, Auranen A, et al
    Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00205.
    PubMed     Abstract available


  49. BIZZARRI N, Marchetti C, Conte C, Loverro M, et al
    The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2022 Apr 6. pii: S0090-8258(22)00206.
    PubMed     Abstract available


  50. HENNO S, Jeanne C, Rouge TM, Genestie C, et al
    Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).
    Gynecol Oncol. 2022 Apr 4. pii: S0090-8258(22)00201.
    PubMed     Abstract available


  51. VAN DER PLOEG P, Uittenboogaard A, Bosch SL, van Diest PJ, et al
    Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium.
    Gynecol Oncol. 2022;165:114-120.
    PubMed     Abstract available


    March 2022
  52. MARINELLI LM, Kisiel JB, Slettedahl SW, Mahoney DW, et al
    Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00200.
    PubMed     Abstract available


  53. SIMILA-MAARALA J, Soovares P, Pasanen A, Ahvenainen T, et al
    TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Gynecol Oncol. 2022 Mar 31. pii: S0090-8258(22)00198.
    PubMed     Abstract available


  54. LIM H, In Shim J, Park SJ, Noh J, et al
    Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery.
    Gynecol Oncol. 2022 Mar 30. pii: S0090-8258(22)00196.
    PubMed     Abstract available


  55. STELTEN S, van Lonkhuijzen LRCW, Hartman YAW, van Driel WJ, et al
    Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study.
    Gynecol Oncol. 2022 Mar 22. pii: S0090-8258(22)00182.
    PubMed     Abstract available


  56. SHIM JI, Ryu JY, Jeong SY, Cho YJ, et al
    Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 16. pii: S0090-8258(22)00176.
    PubMed     Abstract available


  57. MOUKARZEL LA, Ferrando L, Dopeso H, Stylianou A, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Gynecol Oncol. 2022 Mar 12. pii: S0090-8258(22)00141.
    PubMed     Abstract available


  58. HAWKINS GM, Burkett WC, McCoy AN, Nichols HB, et al
    Differences in the microbial profiles of early stage endometrial cancers between Black and White women.
    Gynecol Oncol. 2022 Mar 8. pii: S0090-8258(22)00142.
    PubMed     Abstract available


  59. CHALIF J, Yao M, Gruner M, Kuznicki M, et al
    Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2022 Mar 7. pii: S0090-8258(22)00065.
    PubMed     Abstract available


  60. SCHNARR KL, Seow H, Pond GR, Helpman L, et al
    The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers.
    Gynecol Oncol. 2022 Mar 2. pii: S0090-8258(22)00129.
    PubMed     Abstract available


    February 2022
  61. GOINS EC, Weber JM, Truong T, Moss HA, et al
    Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.
    Gynecol Oncol. 2022 Feb 28. pii: S0090-8258(22)00069.
    PubMed     Abstract available


  62. FALCONE F, Malzoni M, Carnelli M, Cormio G, et al
    Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
    Gynecol Oncol. 2022 Feb 26. pii: S0090-8258(22)00128.
    PubMed     Abstract available


  63. MATSUO K, Chen L, Guo XM, Roman LD, et al
    Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study.
    Gynecol Oncol. 2022 Feb 25. pii: S0090-8258(22)00126.
    PubMed     Abstract available


  64. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
    Gynecol Oncol. 2022 Feb 23. pii: S0090-8258(22)00124.
    PubMed    


  65. KIM YN, Kim JC, Chung YS, Park J, et al
    Incidence of postoperative thrombotic events in ovarian cancer patients with a de-escalated prophylactic strategy: A retrospective cohort study.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00091.
    PubMed     Abstract available


  66. LAFARGUE CJ, Handley KF, Fleming ND, Nick AM, et al
    Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00090.
    PubMed     Abstract available


  67. ALGERA MD, van Driel WJ, Slangen BFM, Kruitwagen RFPM, et al
    Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the 'Dutch Gynecological Oncology Audit'.
    Gynecol Oncol. 2022 Feb 22. pii: S0090-8258(22)00123.
    PubMed     Abstract available


  68. VANDERSTICHELE A, Loverix L, Busschaert P, Van Nieuwenhuysen E, et al
    Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
    Gynecol Oncol. 2022 Feb 14. pii: S0090-8258(22)00073.
    PubMed     Abstract available


  69. PARK J, Kim SI, Jeong SY, Kim Y, et al
    Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Gynecol Oncol. 2022 Feb 10. pii: S0090-8258(22)00086.
    PubMed     Abstract available


  70. WAGAR MK, Mojdehbakhsh RP, Godecker A, Rice LW, et al
    Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    Gynecol Oncol. 2022 Feb 7. pii: S0090-8258(22)00071.
    PubMed     Abstract available


  71. LEMON LS, Orr B, Modugno F, Buckanovich RJ, et al
    Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?
    Gynecol Oncol. 2022 Feb 6. pii: S0090-8258(22)00049.
    PubMed     Abstract available


  72. JOLY F, Fabbro M, Follana P, Lequesne J, et al
    A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
    Gynecol Oncol. 2022 Feb 2. pii: S0090-8258(22)00048.
    PubMed     Abstract available


    January 2022
  73. TRILLSCH F, Mahner S, Ataseven B, Asher R, et al
    Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
    Gynecol Oncol. 2022 Jan 31. pii: S0090-8258(22)00050.
    PubMed     Abstract available


  74. RAIMONDO D, Raffone A, Zakhari A, Maletta M, et al
    The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2022 Jan 25. pii: S0090-8258(22)00046.
    PubMed     Abstract available


  75. COLOMBO N, Tomao F, Benedetti Panici P, Nicoletto MO, et al
    Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00023.
    PubMed     Abstract available


  76. XIA YY, Gronwald J, Karlan B, Lubinski J, et al
    Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00022.
    PubMed     Abstract available


  77. BOUCHARD-FORTIER G, Gien LT, Sutradhar R, Chan WC, et al
    Impact of care by gynecologic oncologists on primary ovarian cancer survival: A population-based study.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(22)00004.
    PubMed     Abstract available


  78. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Gynecol Oncol. 2022 Jan 18. pii: S0090-8258(21)01693.
    PubMed     Abstract available


  79. ZHANG J, Yu S, Li Q, Wang Q, et al
    Increased co-expression of MEST and BRCA1 is associated with worse prognosis and immune infiltration in ovarian cancer.
    Gynecol Oncol. 2022 Jan 15. pii: S0090-8258(22)00018.
    PubMed     Abstract available


  80. FIEGL H, Hagenbuchner J, Kyvelidou C, Seeber B, et al
    Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.
    Gynecol Oncol. 2022 Jan 12. pii: S0090-8258(22)00009.
    PubMed     Abstract available


  81. WEINMANN S, Phillips S, Sweet K, Cosgrove CM, et al
    Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01695.
    PubMed     Abstract available


  82. LIN DI, Fine A, Danziger NA, Huang RSP, et al
    Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    Gynecol Oncol. 2022 Jan 5. pii: S0090-8258(21)01698.
    PubMed     Abstract available


  83. SHALOWITZ DI, DeMari JA
    Defining the essential role of the gynecologic oncologist in rural ovarian cancer care delivery.
    Gynecol Oncol. 2022;164:1-2.
    PubMed    


    December 2021
  84. CORRIGAN KL, Yoder A, De B, Lin L, et al
    Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.
    Gynecol Oncol. 2021 Dec 30. pii: S0090-8258(21)01690.
    PubMed     Abstract available


  85. BEESLEY VL, Ross TL, King MT, Campbell R, et al
    Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01632.
    PubMed     Abstract available


  86. REIJNTJES B, van Suijlichem M, Woolderink JM, Bongers MY, et al
    Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial.
    Gynecol Oncol. 2021 Dec 23. pii: S0090-8258(21)01676.
    PubMed     Abstract available


  87. PHILP L, Alimena S, Ferris W, Saini A, et al
    Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    Gynecol Oncol. 2021 Dec 22. pii: S0090-8258(21)01674.
    PubMed     Abstract available


  88. HARTER P, Mouret-Reynier MA, Pignata S, Cropet C, et al
    Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01673.
    PubMed     Abstract available


  89. MONK BJ, Smith G, Lima J, Long GH, et al
    Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
    Gynecol Oncol. 2021 Dec 21. pii: S0090-8258(21)01634.
    PubMed     Abstract available


  90. KO EM, Bekelman JE, Hicks-Courant K, Brensinger CM, et al
    Association of gynecologic oncology versus medical oncology specialty with survival, utilization, and spending for treatment of gynecologic cancers.
    Gynecol Oncol. 2021 Dec 20. pii: S0090-8258(21)01627.
    PubMed     Abstract available


  91. AGHAJANIAN C, Swisher EM, Okamoto A, Steffensen KD, et al
    Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Gynecol Oncol. 2021 Dec 17. pii: S0090-8258(21)01638.
    PubMed     Abstract available


  92. HA HI, Park EY, Eoh KJ, Lee YJ, et al
    Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Gynecol Oncol. 2021 Dec 16. pii: S0090-8258(21)01639.
    PubMed     Abstract available


  93. SWIFT BE, Maeda A, Bouchard-Fortier G
    Low incidence of venous thromboembolism after gynecologic oncology surgery: Who is at greatest risk?
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01637.
    PubMed     Abstract available


  94. ZHOU ZN, Chen L, Melamed A, St Clair CM, et al
    Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer.
    Gynecol Oncol. 2021 Dec 14. pii: S0090-8258(21)01631.
    PubMed     Abstract available


  95. SWISHER EM, Aghajanian C, O'Malley DM, Fleming GF, et al
    Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Gynecol Oncol. 2021 Dec 11. pii: S0090-8258(21)01630.
    PubMed     Abstract available


  96. HODGSON DR, Brown JS, Dearden SP, Lai Z, et al
    Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    Gynecol Oncol. 2021;163:563-568.
    PubMed     Abstract available


    November 2021
  97. JOHN CS, Fong A, Alban R, Gillen J, et al
    Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    Gynecol Oncol. 2021 Nov 30. pii: S0090-8258(21)01521.
    PubMed     Abstract available


  98. DUPONT NC, Enserro D, Brady MF, Moxley K, et al
    Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2021 Nov 29. pii: S0090-8258(21)01607.
    PubMed     Abstract available


  99. MOYA-ALARCON C, Gonzalez-Dominguez A, Ivanova-Markova Y, Gimeno-Ballester V, et al
    Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01604.
    PubMed     Abstract available


  100. CIANCI S, Fedele C, Vizzielli G, Pasciuto T, et al
    Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON.
    Gynecol Oncol. 2021 Nov 26. pii: S0090-8258(21)01605.
    PubMed     Abstract available


  101. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693].
    Gynecol Oncol. 2021 Nov 19. pii: S0090-8258(21)01601.
    PubMed    


  102. MATUSZEWSKA K, Ten Kortenaar S, Pereira M, Santry LA, et al
    Addition of an Fc-IgG induces receptor clustering and increases the in vitro efficacy and in vivo anti-tumor properties of the thrombospondin-1 type I repeats (3TSR) in a mouse model of advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Nov 16. pii: S0090-8258(21)01599.
    PubMed     Abstract available


  103. MATTHEWS BJ, Qureshi MM, Fiascone SJ, Nitschmann CC, et al
    Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
    Gynecol Oncol. 2021 Nov 13. pii: S0090-8258(21)01553.
    PubMed     Abstract available


  104. WEEKS KS, Lynch CF, West M, Carnahan R, et al
    Gynecologic oncologist impact on adjuvant chemotherapy care for stage II-IV ovarian cancer patients.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01555.
    PubMed     Abstract available


  105. KHOJA L, Weber RP, Webb PM, Jordan SJ, et al
    Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.
    Gynecol Oncol. 2021 Nov 11. pii: S0090-8258(21)01552.
    PubMed     Abstract available


  106. MANNING-GEIST BL, Gordhandas SB, Giri DD, Iasonos A, et al
    Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01551.
    PubMed     Abstract available


  107. FABER MT, Horsbol TA, Baandrup L, Dalton SO, et al
    Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996-2017.
    Gynecol Oncol. 2021 Nov 8. pii: S0090-8258(21)01554.
    PubMed     Abstract available


    October 2021
  108. ROCCONI RP, Wilhite AM, Schambeau L, Scalici J, et al
    A novel proteomic-based screening method for ovarian cancer using cervicovaginal fluids: A window into the abdomen.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01527.
    PubMed     Abstract available


  109. CALO CA, Smith BQ, Dorayappan KDP, Saini U, et al
    Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Gynecol Oncol. 2021 Oct 29. pii: S0090-8258(21)01520.
    PubMed     Abstract available


  110. GOLDBERG RM, Kim SR, Fazelzad R, Li X, et al
    Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Oct 27. pii: S0090-8258(21)01524.
    PubMed     Abstract available


  111. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study.
    Gynecol Oncol. 2021 Oct 26. pii: S0090-8258(21)01525.
    PubMed     Abstract available


  112. SOOVARES P, Pasanen A, Simila-Maarala J, Butzow R, et al
    Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade.
    Gynecol Oncol. 2021 Oct 25. pii: S0090-8258(21)01522.
    PubMed     Abstract available


  113. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    PubMed     Abstract available


  114. WITJES VM, van Bommel MHD, Ligtenberg MJL, Vos JR, et al
    Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01516.
    PubMed     Abstract available


  115. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    PubMed     Abstract available


  116. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    PubMed    


  117. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    PubMed     Abstract available


  118. GERNIER F, Gompel A, Rousset-Jablonski C, Kalbacher E, et al
    Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
    Gynecol Oncol. 2021 Oct 11. pii: S0090-8258(21)01419.
    PubMed     Abstract available


  119. KONECNY GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, et al
    Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 9. pii: S0090-8258(21)01413.
    PubMed     Abstract available


  120. LIU J, Burris H, Wang JS, Barroilhet L, et al
    An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2021 Oct 6. pii: S0090-8258(21)01403.
    PubMed     Abstract available


  121. SHAH PD, Wethington SL, Pagan C, Latif N, et al
    Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Gynecol Oncol. 2021 Oct 4. pii: S0090-8258(21)01322.
    PubMed     Abstract available


  122. TEWARIE NMSB, van Driel WJ, van Ham M, Wouters MW, et al
    Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01392.
    PubMed    


  123. CLAIR KH, Bristow RE
    The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.
    Gynecol Oncol. 2021;163:3-4.
    PubMed    


  124. ALHILLI MM, Rybicki L, Carr C, Yao M, et al
    Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Oct 1. pii: S0090-8258(21)01377.
    PubMed     Abstract available


    September 2021
  125. SWISHER EM, Kristeleit RS, Oza AM, Tinker AV, et al
    Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01329.
    PubMed     Abstract available


  126. HA HI, Cho SH, Lim J, Lee YJ, et al
    Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01383.
    PubMed     Abstract available


  127. AZZALINI E, Barbazza R, Stanta G, Giorda G, et al
    Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01382.
    PubMed     Abstract available


  128. LI JY, Park HS, Huang GS, Young MR, et al
    Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
    Gynecol Oncol. 2021 Sep 30. pii: S0090-8258(21)01391.
    PubMed     Abstract available


  129. BRYK S, Katuwal S, Haltia UM, Tapper J, et al
    Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
    Gynecol Oncol. 2021 Sep 28. pii: S0090-8258(21)01381.
    PubMed     Abstract available


  130. ATASEVEN B, Tripon D, Schwameis R, Harter P, et al
    Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01335.
    PubMed     Abstract available


  131. RESHKO LB, Gaskins JT, Rattani A, Farley AA, et al
    Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.
    Gynecol Oncol. 2021 Sep 23. pii: S0090-8258(21)01375.
    PubMed     Abstract available


  132. LEE SJ, Kim YH, Lee MY, Ko HS, et al
    Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.
    Gynecol Oncol. 2021 Sep 21. pii: S0090-8258(21)01376.
    PubMed     Abstract available


  133. HUANG T, Townsend MK, Dood RL, Sood AK, et al
    Antihypertensive medication use and ovarian cancer survival.
    Gynecol Oncol. 2021 Sep 20. pii: S0090-8258(21)01378.
    PubMed     Abstract available


  134. WENZEL L, Huang HQ, Cella D, McKinney CO, et al
    Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
    Gynecol Oncol. 2021 Sep 18. pii: S0090-8258(21)01326.
    PubMed     Abstract available


  135. GAILLARD S, Oaknin A, Ray-Coquard I, Vergote I, et al
    Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gynecol Oncol. 2021 Sep 11. pii: S0090-8258(21)01330.
    PubMed     Abstract available


  136. MOSS HA, Chen L, Hershman DL, Davidson B, et al
    Adherence to PARP inhibitor therapy among women with ovarian cancer.
    Gynecol Oncol. 2021 Sep 9. pii: S0090-8258(21)01323.
    PubMed     Abstract available


  137. WANG Z, Guo E, Yang B, Xiao R, et al
    Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer.
    Gynecol Oncol. 2021 Sep 7. pii: S0090-8258(21)01327.
    PubMed     Abstract available


  138. WERNER B, Yuwono N, Duggan J, Liu D, et al
    Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
    Gynecol Oncol. 2021;162:720-727.
    PubMed     Abstract available


  139. CAMPBELL R, King MT, Ross TL, Cohen PA, et al
    Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment.
    Gynecol Oncol. 2021 Sep 1. pii: S0090-8258(21)01320.
    PubMed     Abstract available


    August 2021
  140. FUH KC, Bookman MA, Liu JF, Coleman RL, et al
    Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Gynecol Oncol. 2021 Aug 30. pii: S0090-8258(21)01318.
    PubMed     Abstract available


  141. STEENBEEK MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, et al
    Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    Gynecol Oncol. 2021 Aug 26. pii: S0090-8258(21)01317.
    PubMed     Abstract available


  142. POZZAR RA, Xiong N, Hong F, Wright AA, et al
    Perceived patient-centered communication, quality of life, and symptom burden in individuals with ovarian cancer.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)00652.
    PubMed     Abstract available


  143. EBINA Y, Yamagami W, Kobayashi Y, Tabata T, et al
    Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: A JSGO-JSOG joint study.
    Gynecol Oncol. 2021 Aug 25. pii: S0090-8258(21)01310.
    PubMed     Abstract available


  144. TAMURA R, Yoshihara K, Matsuo K, Yachida N, et al
    Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01307.
    PubMed     Abstract available


  145. SOMASEGAR S, Weiss AS, Norquist BM, Khasnavis N, et al
    Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    Gynecol Oncol. 2021 Aug 24. pii: S0090-8258(21)01315.
    PubMed     Abstract available


  146. D'AMORA P, Silva IDCG, Tewari KS, Bristow RE, et al
    Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)00646.
    PubMed     Abstract available


  147. D'ALESSANDRIS N, Travaglino A, Santoro A, Arciuolo D, et al
    TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    Gynecol Oncol. 2021 Aug 23. pii: S0090-8258(21)01309.
    PubMed     Abstract available


  148. COWAN M, Swetzig WM, Adorno-Cruz V, Pineda MJ, et al
    Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Gynecol Oncol. 2021 Aug 18. pii: S0090-8258(21)00650.
    PubMed     Abstract available


  149. BANERJEE SN, Tang M, O'Connell RL, Sjoquist K, et al
    A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
    Gynecol Oncol. 2021 Aug 16. pii: S0090-8258(21)00586.
    PubMed     Abstract available


  150. LUTGENDORF SK, Ramirez E, Schrepf A, Valentine MC, et al
    Rural residence is related to shorter survival in epithelial ovarian cancer patients.
    Gynecol Oncol. 2021 Aug 13. pii: S0090-8258(21)00601.
    PubMed     Abstract available


  151. PARK M, Lim J, Lee JA, Park HJ, et al
    Incidence and outcomes of malignant ovarian germ cell tumors in Korea, 1999-2017.
    Gynecol Oncol. 2021 Aug 12. pii: S0090-8258(21)00645.
    PubMed     Abstract available


  152. WETHINGTON SL, Wahner-Hendrickson AE, Swisher EM, Kaufmann SH, et al
    PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
    Gynecol Oncol. 2021 Aug 11. pii: S0090-8258(21)00647.
    PubMed    


  153. WENTZENSEN N, O'Brien KM
    Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence.
    Gynecol Oncol. 2021 Aug 5. pii: S0090-8258(21)00598.
    PubMed     Abstract available


  154. COLOMBO N, Moore K, Scambia G, Oaknin A, et al
    Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
    Gynecol Oncol. 2021 Aug 2. pii: S0090-8258(21)00578.
    PubMed     Abstract available


  155. SALANI R, Liu JF
    The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts.
    Gynecol Oncol. 2021;162:245-248.
    PubMed    


  156. GROENEWEG JW, Roze JF, Peters EDJ, Sereno F, et al
    FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
    Gynecol Oncol. 2021;162:413-420.
    PubMed     Abstract available


    July 2021
  157. BANTIE L, Tadesse S, Likisa J, Yu M, et al
    Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].
    Gynecol Oncol. 2021 Jul 30. pii: S0090-8258(21)00580.
    PubMed    


  158. VILLANUEVA C, Chang J, Ziogas A, Bristow RE, et al
    Ambient air pollution and ovarian cancer survival in California.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00602.
    PubMed     Abstract available


  159. NANEZ A, Stram DA, Garcia C, Powell CB, et al
    Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
    Gynecol Oncol. 2021 Jul 27. pii: S0090-8258(21)00600.
    PubMed     Abstract available


  160. LAZURKO C, Clark M, Pulman K, Lennox G, et al
    Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Gynecol Oncol. 2021 Jul 26. pii: S0090-8258(21)00589.
    PubMed     Abstract available


  161. BASARAN D, Boerner T, Suhner J, Sassine D, et al
    Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00592.
    PubMed     Abstract available


  162. MARCHETTI C, Rosati A, De Felice F, Boccia SM, et al
    Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    Gynecol Oncol. 2021 Jul 23. pii: S0090-8258(21)00587.
    PubMed     Abstract available


  163. EOH KJ, Park EY, Chang YJ, Ha HI, et al
    The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jul 22. pii: S0090-8258(21)00590.
    PubMed     Abstract available


  164. MOSS HA, Perhanidis JA, Havrilesky LJ, Secord AA, et al
    Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 20. pii: S0090-8258(21)00588.
    PubMed     Abstract available


  165. CIBULA D, Rob L, Mallmann P, Knapp P, et al
    Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00533.
    PubMed     Abstract available


  166. DE NONNEVILLE A, Zemmour C, Frank S, Joly F, et al
    Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
    Gynecol Oncol. 2021 Jul 19. pii: S0090-8258(21)00581.
    PubMed     Abstract available


  167. ZENG H, Chen L, Zhang M, Luo Y, et al
    Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00577.
    PubMed     Abstract available


  168. RASMUSSEN M, Lim K, Rambech E, Andersen MH, et al
    Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Gynecol Oncol. 2021 Jul 15. pii: S0090-8258(21)00531.
    PubMed     Abstract available


  169. GHONIEM K, Larish AM, Dinoi G, Zhou XC, et al
    Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Gynecol Oncol. 2021 Jul 14. pii: S0090-8258(21)00526.
    PubMed     Abstract available


  170. KURODA Y, Chiyoda T, Kawaida M, Nakamura K, et al
    ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00536.
    PubMed     Abstract available


  171. BACKES FJ, Wei L, Chen M, Hill K, et al
    Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
    Gynecol Oncol. 2021 Jul 13. pii: S0090-8258(21)00528.
    PubMed     Abstract available


  172. HERMENS M, van Altena AM, Bulten J, van Vliet HAAM, et al
    Increased incidence of ovarian cancer in both endometriosis and adenomyosis.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00535.
    PubMed     Abstract available


  173. HUFFMAN DL, Jayakrishnan TT, Shankar K, Peterson CE, et al
    Disparities in ovarian cancer treatment and overall survival according to race: An update.
    Gynecol Oncol. 2021 Jul 12. pii: S0090-8258(21)00541.
    PubMed     Abstract available


  174. VAN DER PLOEG P, Uittenboogaard A, Thijs AMJ, Westgeest HM, et al
    The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00538.
    PubMed     Abstract available


  175. KIM SR, Malcolmson J, Li X, Bernardini MQ, et al
    The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2021 Jul 10. pii: S0090-8258(21)00540.
    PubMed     Abstract available


  176. GRUNER M, Chambers LM, Yao M, Chichura A, et al
    Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00530.
    PubMed     Abstract available


  177. SULLIVAN MW, Philp L, Kanbergs AN, Safdar N, et al
    Lymph node assessment at the time of hysterectomy has limited clinical utility for patients with pre-cancerous endometrial lesions.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00534.
    PubMed     Abstract available


  178. GADDUCCI A, Multinu F, Cosio S, Carinelli S, et al
    Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
    Gynecol Oncol. 2021 Jul 8. pii: S0090-8258(21)00529.
    PubMed     Abstract available


  179. KRASNER CN, Campos SM, Young CL, Chadda KR, et al
    Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2021 Jul 6. pii: S0090-8258(21)00532.
    PubMed     Abstract available


  180. HILLMAN RT, Lin DI, Lawson B, Gershenson DM, et al
    Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2021 Jul 5. pii: S0090-8258(21)00518.
    PubMed     Abstract available


    June 2021
  181. BENOIT L DR, Zerbib J Dr, Koual M Dr, Nguyen-Xuan HT Dr, et al
    What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Gynecol Oncol. 2021 Jun 30. pii: S0090-8258(21)00521.
    PubMed     Abstract available


  182. SAFRA T, Waissengrin B, Gerber D, Bernstein-Molho R, et al
    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    Gynecol Oncol. 2021 Jun 22. pii: S0090-8258(21)00489.
    PubMed     Abstract available


  183. WAGAR MK, Sobecki JN, Chandereng T, Hartenbach EM, et al
    Postoperative venous thromboembolism in gynecologic oncology patients undergoing minimally invasive surgery: Does modality matter?
    Gynecol Oncol. 2021 Jun 17. pii: S0090-8258(21)00491.
    PubMed     Abstract available


  184. BALDEWPERSAD TEWARIE NMS, van Driel WJ, van Ham M, Wouters MW, et al
    Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA).
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00436.
    PubMed     Abstract available


  185. JIANG C, Li Z
    Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Jun 16. pii: S0090-8258(21)00483.
    PubMed     Abstract available


  186. FAN Y, Zhang YF, Wang MY, Mu Y, et al
    Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Jun 9. pii: S0090-8258(21)00439.
    PubMed     Abstract available


  187. HICKEY M, Moss KM, Krejany EO, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2021 Jun 8. pii: S0090-8258(21)00442.
    PubMed     Abstract available


  188. VAN DER ZANDEN V, van Soolingen NJ, Viddeleer AR, Trum JW, et al
    Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00445.
    PubMed     Abstract available


  189. AGHAJANIAN C, Bookman MA, Fleming GF, Swisher EM, et al
    Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    Gynecol Oncol. 2021 Jun 7. pii: S0090-8258(21)00437.
    PubMed     Abstract available


  190. CASPER AC, Parsons MW, Chipman J, Burt LM Jr, et al
    Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00440.
    PubMed     Abstract available


  191. LI S, Bercow AS, Falzone M, Kalyanaraman R, et al
    Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00438.
    PubMed     Abstract available


  192. HANLEY GE, Kaur P, Berchuck A, Chase A, et al
    Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
    Gynecol Oncol. 2021 Jun 3. pii: S0090-8258(21)00427.
    PubMed     Abstract available


  193. ALVAREZ SECORD A, O'Malley DM, Sood AK, Westin SN, et al
    Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Gynecol Oncol. 2021 Jun 2. pii: S0090-8258(21)00424.
    PubMed     Abstract available


  194. SHARMA A, Singh M, Chauhan R, Malik PS, et al
    Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00431.
    PubMed     Abstract available


  195. SUE-A-QUAN R, Patel PG, Shakfa N, Nyi MN, et al
    Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
    Gynecol Oncol. 2021 Jun 1. pii: S0090-8258(21)00406.
    PubMed     Abstract available


    May 2021
  196. FRANGOU E, Bertelli G, Love S, Mackean MJ, et al
    OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.
    Gynecol Oncol. 2021 May 28. pii: S0090-8258(21)00430.
    PubMed     Abstract available


  197. HAVRILESKY LJ, Scott AL, Davidson BA, Secord AA, et al
    The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00428.
    PubMed     Abstract available


  198. DE JONG JM, Hoogendam JP, Braat AJAT, Zweemer RP, et al
    The feasibility of folate receptor alpha- and HER2-targeted intraoperative fluorescence-guided cytoreductive surgery in women with epithelial ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 May 27. pii: S0090-8258(21)00423.
    PubMed     Abstract available


  199. MANNING-GEIST BL, Chi DS, Long Roche K, Zivanovic O, et al
    Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Gynecol Oncol. 2021 May 25. pii: S0090-8258(21)00421.
    PubMed     Abstract available


  200. LIN J, Sharaf RN, Saganty R, Ahsan D, et al
    Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    Gynecol Oncol. 2021 May 19. pii: S0090-8258(21)00407.
    PubMed     Abstract available


  201. HEMMINGSEN CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, et al
    The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Gynecol Oncol. 2021 May 17. pii: S0090-8258(21)00404.
    PubMed     Abstract available


  202. KIM SI, Yoon S, Kim TM, Cho JY, et al
    Prognostic implications of body composition change during primary treatment in patients with ovarian cancer: A retrospective study using an artificial intelligence-based volumetric technique.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00363.
    PubMed     Abstract available


  203. TRAN DT, Vo VK, Le MT, Chuang L, et al
    Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
    Gynecol Oncol. 2021 May 13. pii: S0090-8258(21)00360.
    PubMed     Abstract available


  204. CABRERA S, Barahona-Orpinell M, Almansa-Gonzalez C, Padilla-Iserte P, et al
    Combined use of ICG and technetium does not improve sentinel lymph node detection in endometrial cancer: Results of the COMBITEC study.
    Gynecol Oncol. 2021 May 12. pii: S0090-8258(21)00361.
    PubMed     Abstract available


  205. HICKEY M, Moss KM, Mishra GD, Krejany EO, et al
    What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 May 7. pii: S0090-8258(21)00358.
    PubMed     Abstract available


  206. CAO L, Wei M, Liu Y, Fu J, et al
    Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses.
    Gynecol Oncol. 2021 May 6. pii: S0090-8258(21)00351.
    PubMed     Abstract available


  207. CHAM S, Huang Y, Melamed A, Worley MJ Jr, et al
    Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival.
    Gynecol Oncol. 2021 May 5. pii: S0090-8258(21)00352.
    PubMed     Abstract available


  208. GAMBLE CR, Huang Y, Wright JD, Hou JY, et al
    Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance.
    Gynecol Oncol. 2021 May 3. pii: S0090-8258(21)00345.
    PubMed     Abstract available


  209. SIMS TT, Boruta DM
    Sentinel lymph node isolated tumor cells in early staged endometrioid endometrial cancer: Utility or futility?
    Gynecol Oncol. 2021;161:331-332.
    PubMed    


  210. GILLEN J, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecol Oncol. 2021;161:512-515.
    PubMed     Abstract available


    April 2021
  211. MULLINS MA, Ruterbusch JJ, Clarke P, Uppal S, et al
    Continuity of care and receipt of aggressive end of life care among women dying of ovarian cancer.
    Gynecol Oncol. 2021 Apr 27. pii: S0090-8258(21)00344.
    PubMed     Abstract available


  212. GIANNONE G, Scotto G, Katsaros D, De Giorgi U, et al
    Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature.
    Gynecol Oncol. 2021 Apr 22. pii: S0090-8258(21)00328.
    PubMed     Abstract available


  213. THUSGAARD CF, Korsholm M, Koldby KM, Kruse TA, et al
    Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review.
    Gynecol Oncol. 2021 Apr 20. pii: S0090-8258(21)00330.
    PubMed     Abstract available


  214. SWAYZE EJ, Strzyzewski L, Avula P, Zebolsky AL, et al
    The impact of expanding gynecologic oncology care to ovarian cancer patients in small cities and rural communities.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00331.
    PubMed     Abstract available


  215. MARTINEZ A, Buckley M, Scalise CB, Katre AA, et al
    Understanding the effect of mechanical forces on ovarian cancer progression.
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00273.
    PubMed     Abstract available


  216. ARTIOLI G, Giannone G, Valabrega G, Maggiorotto F, et al
    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
    Gynecol Oncol. 2021 Apr 19. pii: S0090-8258(21)00324.
    PubMed     Abstract available


  217. DENG M, Wu D, Zhang Y, Jin Z, et al
    MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00323.
    PubMed     Abstract available


  218. SHIM SH, Chae SH, So KA, Lee SJ, et al
    Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2021 Apr 17. pii: S0090-8258(21)00270.
    PubMed     Abstract available


  219. NITECKI R, Fleming ND, Fellman BM, Meyer LA, et al
    Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00322.
    PubMed     Abstract available


  220. GUPTA VG, Hirst J, Petersen S, Roby KF, et al
    Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecol Oncol. 2021 Apr 15. pii: S0090-8258(21)00325.
    PubMed     Abstract available


  221. TONE AA, McCuaig JM, Ricker N, Boghosian T, et al
    The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Gynecol Oncol. 2021 Apr 13. pii: S0090-8258(21)00321.
    PubMed     Abstract available


  222. VAN DE VORST REWM, Hoogendam JP, van der Aa MA, Witteveen PO, et al
    The attributive value of comprehensive surgical staging in clinically early-stage epithelial ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Apr 10. pii: S0090-8258(21)00317.
    PubMed     Abstract available


  223. FLEMING ND, Westin SN, Rauh-Hain JA, Soliman PT, et al
    Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
    Gynecol Oncol. 2021 Apr 7. pii: S0090-8258(21)00272.
    PubMed     Abstract available


  224. CHASE DM, Neighbors J, Perhanidis J, Monk BJ, et al
    Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay.
    Gynecol Oncol. 2021 Apr 1. pii: S0090-8258(21)00259.
    PubMed     Abstract available


  225. CRAMER DW, Vitonis AF, Sasamoto N, Yamamoto H, et al
    Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES).
    Gynecol Oncol. 2021;161:282-290.
    PubMed     Abstract available


  226. JOU J, Zimmer Z, Charo L, Yau C, et al
    HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
    Gynecol Oncol. 2021;161:25-33.
    PubMed     Abstract available


    March 2021
  227. MALLEN A, Todd S, Robertson SE, Kim J, et al
    Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00228.
    PubMed     Abstract available


  228. RAFFONE A, Catena U, Travaglino A, Masciullo V, et al
    Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00267.
    PubMed     Abstract available


  229. GEOFFRON S, Lier A, de Kermadec E, Sermondade N, et al
    Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG).
    Gynecol Oncol. 2021 Mar 31. pii: S0090-8258(21)00268.
    PubMed     Abstract available


  230. GIL-MORENO A, Alonso-Alconada L, Diaz-Feijoo B, Domingo S, et al
    M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients.
    Gynecol Oncol. 2021 Mar 29. pii: S0090-8258(21)00260.
    PubMed     Abstract available


  231. FALCONE F, Breda E, Ferrandina G, Malzoni M, et al
    Fertility-sparing treatment in advanced-stage serous borderline ovarian tumors. An analysis from the MITO14 study database.
    Gynecol Oncol. 2021 Mar 26. pii: S0090-8258(21)00261.
    PubMed     Abstract available


  232. CARTMEL B, Hughes M, Ercolano EA, Gottlieb L, et al
    Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00195.
    PubMed     Abstract available


  233. FILIPPOVA OT, Tin AL, Alonso J, Vickers AJ, et al
    Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00252.
    PubMed     Abstract available


  234. ZHANG X, Devins K, Ko EM, Reyes MC, et al
    Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Gynecol Oncol. 2021 Mar 24. pii: S0090-8258(21)00257.
    PubMed     Abstract available


  235. NASIOUDIS D, Byrne M, Ko EM, Giuntoli RL 2nd, et al
    Outcomes of sentinel lymph node mapping for patients with FIGO stage I endometrioid endometrial carcinoma.
    Gynecol Oncol. 2021 Mar 23. pii: S0090-8258(21)00256.
    PubMed     Abstract available


  236. KONECNY GE, Oza AM, Tinker AV, Oaknin A, et al
    Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Gynecol Oncol. 2021 Mar 19. pii: S0090-8258(21)00235.
    PubMed     Abstract available


  237. LOREEN A, Polen-De C, Monk BJ, Jackson AL, et al
    The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00176.
    PubMed    


  238. HASSELGREN E, Hertzberg D, Camderman T, Bjorne H, et al
    Perioperative fluid balance and major postoperative complications in surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2021 Mar 12. pii: S0090-8258(21)00179.
    PubMed     Abstract available


  239. ROCCONI RP, Monk BJ, Walter A, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Mar 11. pii: S0090-8258(21)00229.
    PubMed     Abstract available


  240. MORDEN CR, Farrell AC, Sliwowski M, Lichtensztejn Z, et al
    Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Gynecol Oncol. 2021 Mar 10. pii: S0090-8258(21)00199.
    PubMed     Abstract available


  241. LAGO V, Montero B, Lopez S, Padilla-Iserte P, et al
    Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00193.
    PubMed     Abstract available


  242. BUECHEL ME, Enserro D, Burger RA, Brady MF, et al
    Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00177.
    PubMed     Abstract available


  243. COWAN R, Nobre SP, Pradhan N, Yasukawa M, et al
    Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    Gynecol Oncol. 2021 Mar 9. pii: S0090-8258(21)00142.
    PubMed     Abstract available


  244. BACKES FJ, Felix AS, Plante M, Gregoire J, et al
    Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
    Gynecol Oncol. 2021 Mar 4. pii: S0090-8258(21)00154.
    PubMed     Abstract available


  245. HUANG C, Lin X, He J, Liu N, et al
    Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00169.
    PubMed     Abstract available


  246. FILIPPOVA OT, Selenica P, Pareja F, Vahdatinia M, et al
    Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Gynecol Oncol. 2021 Mar 2. pii: S0090-8258(21)00173.
    PubMed     Abstract available


  247. AUBREY C, Saad N, Kobel M, Mattatall F, et al
    Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status.
    Gynecol Oncol. 2021 Mar 1. pii: S0090-8258(21)00158.
    PubMed     Abstract available


    February 2021
  248. SCHRIER E, Xiong N, Thompson E, Poort H, et al
    Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00168.
    PubMed     Abstract available


  249. SJOQUIST KM, Espinoza D, Mileshkin L, Ananda S, et al
    REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00109.
    PubMed     Abstract available


  250. AREND RC, Monk BJ, Herzog TJ, Moore KN, et al
    Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum r
    Gynecol Oncol. 2021 Feb 23. pii: S0090-8258(21)00151.
    PubMed     Abstract available


  251. DA CRUZ PAULA A, DeLair DF, Ferrando L, Fix DJ, et al
    Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Gynecol Oncol. 2021 Feb 20. pii: S0090-8258(21)00152.
    PubMed     Abstract available


  252. KURTZ JE, Gebski V, Sukhin V, Carey M, et al
    Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
    Gynecol Oncol. 2021 Feb 18. pii: S0090-8258(21)00155.
    PubMed     Abstract available


  253. INCI MG, Anders L, Woopen H, Richter R, et al
    Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study.
    Gynecol Oncol. 2021 Feb 16. pii: S0090-8258(21)00149.
    PubMed     Abstract available


  254. BAANDRUP L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, et al
    Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00102.
    PubMed     Abstract available


  255. HICKEY M, Moss KM, Brand A, Wrede CD, et al
    What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    Gynecol Oncol. 2021 Feb 11. pii: S0090-8258(21)00108.
    PubMed     Abstract available


  256. DAHM-KAHLER P, Holmberg E, Holtenman M, Radestad AF, et al
    Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2021 Feb 10. pii: S0090-8258(21)00059.
    PubMed     Abstract available


  257. CHAMBERS LM, Yao M, Morton M, Gruner M, et al
    Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00099.
    PubMed     Abstract available


  258. RAHIMY E, Usoz M, von Eyben R, Fujimoto D, et al
    Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors.
    Gynecol Oncol. 2021 Feb 4. pii: S0090-8258(21)00093.
    PubMed     Abstract available


  259. LIU S, Kasherman L, Fazelzad R, Wang L, et al
    The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2021 Feb 2. pii: S0090-8258(21)00088.
    PubMed     Abstract available


    January 2021
  260. HARRISON RF, Cantor SB, Sun CC, Villanueva M, et al
    Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2021 Jan 31. pii: S0090-8258(21)00084.
    PubMed     Abstract available


  261. PIZZOFERRATO AC, Klein M, Fauvet R, Durand C, et al
    Pelvic floor disorders and sexuality in women with ovarian cancer: A systematic review.
    Gynecol Oncol. 2021 Jan 27. pii: S0090-8258(21)00086.
    PubMed     Abstract available


  262. TOZZI R, Traill Z, Valenti G, Ferrari F, et al
    A prospective study on the diagnostic pathway of patients with stage IIIC-IV ovarian cancer: Exploratory laparoscopy (EXL) + CT scan VS. CT scan.
    Gynecol Oncol. 2021 Jan 26. pii: S0090-8258(21)00060.
    PubMed     Abstract available


  263. KIM SR, Tone A, Kim RH, Cesari M, et al
    Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
    Gynecol Oncol. 2021 Jan 18. pii: S0090-8258(21)00002.
    PubMed     Abstract available


  264. NOVIKOVA OV, Nosov VB, Panov VA, Novikova EG, et al
    Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
    Gynecol Oncol. 2021 Jan 15. pii: S0090-8258(21)00001.
    PubMed     Abstract available


  265. CASTLE PE, Locke A, Tergas AI, Befano B, et al
    The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(21)00052.
    PubMed     Abstract available


  266. SCHEEPERS ERM, de Rooij BH, Pijnenborg JMA, van Huis-Tanja LH, et al
    Perceived social support in patients with endometrial or ovarian cancer: A secondary analysis from the ROGY care study.
    Gynecol Oncol. 2021 Jan 13. pii: S0090-8258(20)34246.
    PubMed     Abstract available


  267. BILBAO M, Aikins JK, Ostrovsky O
    Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications.
    Gynecol Oncol. 2021 Jan 9. pii: S0090-8258(20)34248.
    PubMed     Abstract available


  268. HAGEMANN IS, Deng W, Zaino RJ, Powell MA, et al
    The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
    Gynecol Oncol. 2021 Jan 7. pii: S0090-8258(20)34255.
    PubMed     Abstract available


  269. DELLINGER TH, Han ES
    State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Gynecol Oncol. 2021 Jan 5. pii: S0090-8258(20)34243.
    PubMed    


  270. HEUS C, Smorenburg A, Stoker J, Rutten MJ, et al
    Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study.
    Gynecol Oncol. 2021;160:187-192.
    PubMed     Abstract available


  271. FADADU PP, Polen-De CL, McGree ME, Weaver AL, et al
    Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
    Gynecol Oncol. 2021;160:40-44.
    PubMed     Abstract available


    December 2020
  272. DUSKA LR, Krasner CN, O'Malley DM, Hays JL, et al
    A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2020 Dec 31. pii: S0090-8258(20)34228.
    PubMed     Abstract available


  273. BOERNER T, Walch HS, Nguyen B, Iasonos A, et al
    Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    Gynecol Oncol. 2020 Dec 29. pii: S0090-8258(20)34225.
    PubMed     Abstract available


  274. LIANG MI, Chen L, Hershman DL, Hillyer GC, et al
    Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
    Gynecol Oncol. 2020 Dec 27. pii: S0090-8258(20)34218.
    PubMed     Abstract available


  275. GHEZELAYAGH TS, Pennington KP, Norquist BM, Khasnavis N, et al
    Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    Gynecol Oncol. 2020 Dec 26. pii: S0090-8258(20)34178.
    PubMed     Abstract available


  276. PHILP L, Tannenbaum S, Haber H, Saini A, et al
    Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2020 Dec 23. pii: S0090-8258(20)34174.
    PubMed     Abstract available


  277. GUO Y, Jiang T, Ouyang L, Li X, et al
    A novel diagnostic nomogram based on serological and ultrasound findings for preoperative prediction of malignancy in patients with ovarian masses.
    Gynecol Oncol. 2020 Dec 20. pii: S0090-8258(20)34177.
    PubMed     Abstract available


  278. BANVILLE AC, Wouters MCA, Oberg AL, Goergen KM, et al
    Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Gynecol Oncol. 2020 Dec 17. pii: S0090-8258(20)34176.
    PubMed     Abstract available


  279. KARNEZIS AN, Chen SY, Chow C, Yang W, et al
    Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
    Gynecol Oncol. 2020 Dec 13. pii: S0090-8258(20)34175.
    PubMed     Abstract available


  280. YUE H, Li W, Chen R, Wang J, et al
    Stromal POSTN induced by TGF-beta1 facilitates the migration and invasion of ovarian cancer.
    Gynecol Oncol. 2020 Dec 11. pii: S0090-8258(20)34154.
    PubMed     Abstract available


  281. GOTOH O, Kiyotani K, Chiba T, Sugiyama Y, et al
    Immunogenomic landscape of gynecologic carcinosarcoma.
    Gynecol Oncol. 2020 Dec 6. pii: S0090-8258(20)34158.
    PubMed     Abstract available


  282. STOVER EH, Fuh K, Konstantinopoulos PA, Matulonis UA, et al
    Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Gynecol Oncol. 2020;159:887-898.
    PubMed     Abstract available


  283. WANG Z, Yin P, Sun Y, Na L, et al
    LGR4 maintains HGSOC cell epithelial phenotype and stem-like traits.
    Gynecol Oncol. 2020;159:839-849.
    PubMed     Abstract available


  284. FUH K, Mullen M, Blachut B, Stover E, et al
    Homologous recombination deficiency real-time clinical assays, ready or not?
    Gynecol Oncol. 2020;159:877-886.
    PubMed     Abstract available


  285. VETTER MH, Castaneda A, Khan A, O'Malley DM, et al
    A clinical classification system for grading platinum hypersensitivity reactions.
    Gynecol Oncol. 2020;159:794-798.
    PubMed     Abstract available


    November 2020
  286. STRAUBHAR AM, Wolf JL, Zhou MQC, Iasonos A, et al
    Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
    Gynecol Oncol. 2020 Nov 30. pii: S0090-8258(20)34132.
    PubMed     Abstract available


  287. HULSTAERT E, Morlion A, Levanon K, Vandesompele J, et al
    Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review.
    Gynecol Oncol. 2020 Nov 27. pii: S0090-8258(20)34129.
    PubMed     Abstract available


  288. WU L, Zhu J, Yin R, Wu X, et al
    Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Gynecol Oncol. 2020 Nov 26. pii: S0090-8258(20)34013.
    PubMed     Abstract available


  289. CONSIDINE DPC, Jia G, Shu X, Schildkraut JM, et al
    Genetically predicted circulating protein biomarkers and ovarian cancer risk.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34127.
    PubMed     Abstract available


  290. CHO A, Lee SW, Park JY, Kim DY, et al
    Continued medical treatment for persistent early endometrial cancer in young women.
    Gynecol Oncol. 2020 Nov 24. pii: S0090-8258(20)34115.
    PubMed     Abstract available


  291. CHELARIU-RAICU A, Nick A, Urban R, Gordinier M, et al
    A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer.
    Gynecol Oncol. 2020 Nov 23. pii: S0090-8258(20)34124.
    PubMed     Abstract available


  292. KHATIB G, Seyfettinoglu S, Guzel AB, Gulec UK, et al
    Feasibility and rationale of a novel approach in advanced ovarian cancer surgery: Bat- shaped en-bloc total peritonectomy and total hysterectomy salpingo-oophorectomy with or without rectosigmoid resection (Sarta-Bat approach).
    Gynecol Oncol. 2020 Nov 21. pii: S0090-8258(20)34122.
    PubMed     Abstract available


  293. FEJZO MS, Chen HW, Anderson L, McDermott MS, et al
    Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34116.
    PubMed     Abstract available


  294. MORSE CB, Voillet V, Bates BM, Chiu EY, et al
    Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34117.
    PubMed     Abstract available


  295. RANA HQ, Kipnis L, Hehir K, Cronin A, et al
    Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    Gynecol Oncol. 2020 Nov 20. pii: S0090-8258(20)34111.
    PubMed     Abstract available


  296. FREY MK, Chapman-Davis E, Glynn SM, Lin J, et al
    Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic.
    Gynecol Oncol. 2020 Nov 19. pii: S0090-8258(20)34128.
    PubMed     Abstract available


  297. XU Y, Jia Y, Zhang Q, Du Y, et al
    Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Nov 18. pii: S0090-8258(20)34121.
    PubMed     Abstract available


  298. WEEKS K, Lynch CF, West M, Carnahan R, et al
    Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients.
    Gynecol Oncol. 2020 Nov 17. pii: S0090-8258(20)34114.
    PubMed     Abstract available


  299. BOERNER T, Tanner E, Filippova O, Zhou QC, et al
    Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34064.
    PubMed     Abstract available


  300. O'TOOLE SA, Huang Y, Norris L, Power Foley M, et al
    HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    Gynecol Oncol. 2020 Nov 16. pii: S0090-8258(20)34112.
    PubMed     Abstract available


  301. CHEN F, Bailey CE, Alvarez RD, Shu XO, et al
    Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
    Gynecol Oncol. 2020 Nov 15. pii: S0090-8258(20)34062.
    PubMed     Abstract available


  302. POORT H, Fenton ATHR, Thompson E, Dinardo MM, et al
    Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34056.
    PubMed     Abstract available


  303. KIMBLE DC, Dvergsten E, Thomeas-McEwing V, Karovic S, et al
    Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer.
    Gynecol Oncol. 2020 Nov 12. pii: S0090-8258(20)34066.
    PubMed     Abstract available


  304. WALL JA, Meza-Perez S, Scalise CB, Katre A, et al
    Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34053.
    PubMed     Abstract available


  305. WESLEY E, Uppendahl LD, Felices M, Dahl C, et al
    Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34051.
    PubMed     Abstract available


  306. BIZZARRI N, du Bois A, Fruscio R, De Felice F, et al
    Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Gynecol Oncol. 2020 Nov 6. pii: S0090-8258(20)34050.
    PubMed     Abstract available


  307. BLANC-DURAND F, Genestie C, Galende EY, Gouy S, et al
    Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
    Gynecol Oncol. 2020 Nov 5. pii: S0090-8258(20)33955.
    PubMed     Abstract available


  308. RUSSELL B, Hawarden A, Gee M, Edmondson RJ, et al
    Propensity score matching confirms that primary surgery or neoadjuvant chemotherapy result in equivalent survival within a comprehensive cohort of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34057.
    PubMed     Abstract available


  309. DIAZ-FEIJOO B, Bebia V, Hernandez A, Gilabert-Estalles J, et al
    Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer.
    Gynecol Oncol. 2020 Nov 4. pii: S0090-8258(20)34060.
    PubMed     Abstract available


    October 2020
  310. RUBINSTEIN MM, Grisham RN, Cadoo K, Kyi C, et al
    A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
    Gynecol Oncol. 2020 Oct 30. pii: S0090-8258(20)34041.
    PubMed     Abstract available


  311. ELAYAPILLAI S, Ramraj S, Benbrook DM, Bieniasz M, et al
    Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
    Gynecol Oncol. 2020 Oct 29. pii: S0090-8258(20)34018.
    PubMed     Abstract available


  312. MATSUO K, Matsuzaki S, Nusbaum DJ, Maoz A, et al
    Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Gynecol Oncol. 2020 Oct 23. pii: S0090-8258(20)34049.
    PubMed     Abstract available


  313. CEPPI L, Grassi T, Galli F, Buda A, et al
    Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)34036.
    PubMed     Abstract available


  314. HALL MR, Dehbi HM, Banerjee S, Lord R, et al
    A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
    Gynecol Oncol. 2020 Oct 16. pii: S0090-8258(20)33958.
    PubMed     Abstract available


  315. BARBER EL, Garg R, Persenaire C, Simon M, et al
    Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
    Gynecol Oncol. 2020 Oct 14. pii: S0090-8258(20)34012.
    PubMed     Abstract available


  316. MORTON M, Chambers LM, Costales AB, Chichura A, et al
    Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 13. pii: S0090-8258(20)33962.
    PubMed     Abstract available


  317. MICHELS J, Genestie C, Dunant A, Caron O, et al
    Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
    Gynecol Oncol. 2020 Oct 12. pii: S0090-8258(20)33960.
    PubMed     Abstract available


  318. HAUNSCHILD CE, Tewari KS
    The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    Gynecol Oncol. 2020 Oct 11. pii: S0090-8258(20)33953.
    PubMed     Abstract available


  319. CARR C, Son J, Yao M, Priyadarshini A, et al
    Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
    Gynecol Oncol. 2020 Oct 9. pii: S0090-8258(20)33949.
    PubMed     Abstract available


  320. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    PubMed     Abstract available


  321. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    PubMed     Abstract available


  322. CICCONE MA, Adams CL, Bowen C, Thakur T, et al
    Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33950.
    PubMed     Abstract available


  323. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    PubMed     Abstract available


  324. GERSHENSON DM, Cobb LP, Sun CC
    Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33959.
    PubMed    


  325. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    PubMed     Abstract available


  326. EAKIN CM, Ewongwo A, Pendleton L, Monk BJ, et al
    Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
    Gynecol Oncol. 2020;159:112-117.
    PubMed     Abstract available


  327. SALANI R, Liu JF
    Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology.
    Gynecol Oncol. 2020;159:13-16.
    PubMed    


  328. CRESTANI A, Benoit L, Touboul C, Pasquier J, et al
    Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment?
    Gynecol Oncol. 2020;159:285-294.
    PubMed     Abstract available


    September 2020
  329. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    PubMed     Abstract available


  330. CHAN JK, Liang SY, Kapp DS, Chan JE, et al
    Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33910.
    PubMed    


  331. LANDOLFO C, Achten ETL, Ceusters J, Baert T, et al
    Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Gynecol Oncol. 2020 Sep 26. pii: S0090-8258(20)33918.
    PubMed     Abstract available


  332. MIRZA MR, Benigno B, Dorum A, Mahner S, et al
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2020 Sep 24. pii: S0090-8258(20)33899.
    PubMed     Abstract available


  333. WICHMANN C, Klotz DM, Zeiler HJ, Hilger RA, et al
    The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33911.
    PubMed     Abstract available


  334. MANRRIQUEZ E, Mandelbaum A, Aguayo E, Zakhour M, et al
    Factors associated with high-cost hospitalizations in elderly ovarian cancer patients.
    Gynecol Oncol. 2020 Sep 23. pii: S0090-8258(20)33919.
    PubMed     Abstract available


  335. CHARO LM, Jou J, Binder P, Hohmann SF, et al
    Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33915.
    PubMed     Abstract available


  336. JOHNSON KE, Popratiloff A, Fan Y, McDonald S, et al
    Analytic comparison of talc in commercially available baby powder and in pelvic tissues resected from ovarian carcinoma patients.
    Gynecol Oncol. 2020 Sep 22. pii: S0090-8258(20)33921.
    PubMed     Abstract available


  337. EAKIN CM, Norton TJ, Monk BJ, Chase DM, et al
    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33817.
    PubMed     Abstract available


  338. MUSORO JZ, Coens C, Greimel E, King MT, et al
    Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Gynecol Oncol. 2020 Sep 21. pii: S0090-8258(20)33900.
    PubMed     Abstract available


  339. WALLBILLICH JJ, Morris RT, Ali-Fehmi R
    Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Gynecol Oncol. 2020 Sep 5. pii: S0090-8258(20)33813.
    PubMed     Abstract available


  340. DI DONATO V, Di Pinto A, Giannini A, Caruso G, et al
    Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Sep 4. pii: S0090-8258(20)33823.
    PubMed     Abstract available


    August 2020
  341. SHEN L, Xie L, Li R, Shan B, et al
    A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33818.
    PubMed     Abstract available


  342. BELL SG, Dalton L, McNeish BL, Fang F, et al
    Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients.
    Gynecol Oncol. 2020 Aug 23. pii: S0090-8258(20)33816.
    PubMed     Abstract available


  343. BOERNER T, Filippova OT, Chi AJ, Iasonos A, et al
    Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study.
    Gynecol Oncol. 2020 Aug 10. pii: S0090-8258(20)33751.
    PubMed     Abstract available


    July 2020
  344. COLOMBO N, Oza AM, Lorusso D, Aghajanian C, et al
    The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Jul 31. pii: S0090-8258(20)31130.
    PubMed     Abstract available


  345. BLANC-DURAND F, Lefeuvre-Plesse C, Ray-Coquard I, Chaltiel D, et al
    Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).
    Gynecol Oncol. 2020 Jul 25. pii: S0090-8258(20)33654.
    PubMed     Abstract available


  346. COBB LP, Sun CC, Iyer R, Nick AM, et al
    The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Gynecol Oncol. 2020 Jul 22. pii: S0090-8258(20)32324.
    PubMed     Abstract available


  347. WEISS AS, Swisher E, Pennington KP, Radke M, et al
    Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    Gynecol Oncol. 2020 Jul 21. pii: S0090-8258(20)32335.
    PubMed     Abstract available


  348. MCCUAIG JM, Care M, Ferguson SE, Kim RH, et al
    Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    Gynecol Oncol. 2020 Jul 13. pii: S0090-8258(20)32333.
    PubMed     Abstract available


  349. PRESSEY JG, Dandoy CE, Pater LE, Sroga Rios J, et al
    Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
    Gynecol Oncol. 2020 Jul 9. pii: S0090-8258(20)31975.
    PubMed     Abstract available


  350. BERNARD L, Boucher J, Helpman L
    Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
    Gynecol Oncol. 2020 Jul 6. pii: S0090-8258(20)32330.
    PubMed     Abstract available


  351. DERQUIN F, Floquet A, Hardy-Bessard AC, Edeline J, et al
    Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.
    Gynecol Oncol. 2020 Jul 2. pii: S0090-8258(20)32315.
    PubMed     Abstract available


  352. BAE-JUMP V
    Unraveling the mystery of clear cell endometrial cancer.
    Gynecol Oncol. 2020;158:1-2.
    PubMed    


    June 2020
  353. SIMPSON AN, Sutradhar R, Ferguson SE, Robertson D, et al
    Perioperative outcomes of women with and without class III obesity undergoing hysterectomy for endometrioid endometrial cancer: A population-based study.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32295.
    PubMed     Abstract available


  354. MARIA S, Faron M, Maulard A, Pautier P, et al
    Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
    Gynecol Oncol. 2020 Jun 19. pii: S0090-8258(20)32304.
    PubMed     Abstract available


  355. PYRZAK A, Chen L, Kocherginsky M, Barber EL, et al
    Radiation and hormonal therapy for primary treatment of stage I endometrial cancer and long-term survival.
    Gynecol Oncol. 2020 Jun 16. pii: S0090-8258(20)31088.
    PubMed     Abstract available


  356. MORRISON A, Nasioudis D
    Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
    Gynecol Oncol. 2020 Jun 5. pii: S0090-8258(20)31121.
    PubMed     Abstract available


  357. VENERIS JT, Mahajan P, Frazier AL
    Contemporary management of ovarian germ cell tumors and remaining controversies.
    Gynecol Oncol. 2020 Jun 4. pii: S0090-8258(20)31075.
    PubMed     Abstract available


  358. CHEN H, Gotimer K, De Souza C, Tepper CG, et al
    Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Gynecol Oncol. 2020;157:783-792.
    PubMed     Abstract available


  359. DUSKA LR, Petroni GR, Varhegyi N, Brown J, et al
    A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Gynecol Oncol. 2020;157:585-592.
    PubMed     Abstract available


    May 2020
  360. SMAZYNSKI J, Hamilton PT, Thornton S, Milne K, et al
    The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Gynecol Oncol. 2020 May 20. pii: S0090-8258(20)30989.
    PubMed     Abstract available


  361. DAI Y, Wang Z, Wang J
    Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
    PubMed     Abstract available


    April 2020
  362. NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
    Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
    Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
    PubMed     Abstract available


  363. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    PubMed     Abstract available


  364. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    PubMed     Abstract available


  365. MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
    Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
    PubMed     Abstract available


    March 2020
  366. RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
    Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
    PubMed     Abstract available


  367. WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
    Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
    PubMed     Abstract available


  368. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    PubMed     Abstract available


  369. REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
    Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
    PubMed     Abstract available


  370. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    PubMed     Abstract available


    February 2020
  371. PLETT H, Harter P, Ataseven B, Heitz F, et al
    Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
    Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
    PubMed     Abstract available


  372. GLASER GE, Kalogera E, Kumar A, Yi J, et al
    Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
    PubMed     Abstract available


  373. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
    PubMed     Abstract available


  374. UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
    Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
    Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
    PubMed     Abstract available


  375. COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
    Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
    PubMed     Abstract available


  376. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    PubMed     Abstract available


    January 2020
  377. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    PubMed     Abstract available


  378. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    PubMed     Abstract available


  379. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    PubMed     Abstract available


  380. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    PubMed     Abstract available


  381. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    PubMed     Abstract available


  382. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    PubMed     Abstract available


  383. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    PubMed     Abstract available


  384. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    PubMed     Abstract available


  385. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    PubMed     Abstract available


    December 2019
  386. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    PubMed     Abstract available


  387. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: